NanoViricides, Inc. (NYSE American: NNVC) announced it has entered into a securities purchase agreement with a single fundamental institutional investor for a registered direct offering expected to generate approximately $3.8 million in gross proceeds. The offering includes the sale of 2,516,339 common shares or pre-funded warrants, along with warrants to purchase an equal number of common shares at an exercise price of $1.75 per share, expiring five and a half years after issuance. D. Boral Capital LLC is serving as exclusive placement agent. The offering is expected to close on or about July 27, 2026, subject to customary conditions.
The funding is a critical step for NanoViricides as it advances its lead drug candidate, NV-387, a broad-spectrum antiviral designed to treat respiratory syncytial virus (RSV), COVID-19, Long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox and measles. The company is currently focused on moving NV-387 into Phase II human clinical trials. The capital infusion will support these efforts, including preclinical and clinical development activities.
NanoViricides specializes in creating nanomaterial-based antiviral therapies. Its proprietary nanoviricide technology, licensed from TheraCour Pharma, Inc., involves designing polymeric micelles that mimic host cell receptors to trap and neutralize viruses. The company holds exclusive, sub-licensable field licenses for multiple viral indications, including HIV, hepatitis B and C, rabies, herpes, influenza, dengue, Ebola, and certain coronaviruses.
The offering underscores investor confidence in NanoViricides' approach and its potential to address unmet medical needs in antiviral therapy. With the rise of viral outbreaks and the limitations of existing treatments, the company's broad-spectrum candidates could offer significant advantages. NV-387, for example, does not encapsulate remdesivir, but the company has also developed NV-CoV-2-R, which encapsulates remdesivir, leveraging the FDA-approved drug's safety profile.
However, the path to drug approval remains challenging. NanoViricides acknowledges the lengthy and capital-intensive nature of pharmaceutical development, and there is no guarantee that any candidate will prove effective or safe in human trials. The company's success depends on continued funding, successful clinical outcomes, and regulatory approvals.
The announcement highlights the ongoing need for innovative antiviral strategies. As the world contends with evolving viral threats, NanoViricides' nanomedicine platform offers a novel mechanism that could complement existing therapies. The $3.8 million raise provides near-term runway to advance its pipeline, but the company will need additional capital to complete clinical development and bring products to market.
